PTAB Invalidates Jevtana Patent Claims In Mylan Challenge
The Patent Trial and Appeal Board has decided much of an Aventis Pharma S.A. patent for the chemotherapy drug Jevtana is invalid, rejecting arguments that the drug's success weighed against finding...To view the full article, register now.
Already a subscriber? Click here to view full article